JP2003183167A - 鮫由来コンドロイチン硫酸鉄コロイド含有注射液 - Google Patents
鮫由来コンドロイチン硫酸鉄コロイド含有注射液Info
- Publication number
- JP2003183167A JP2003183167A JP2002295694A JP2002295694A JP2003183167A JP 2003183167 A JP2003183167 A JP 2003183167A JP 2002295694 A JP2002295694 A JP 2002295694A JP 2002295694 A JP2002295694 A JP 2002295694A JP 2003183167 A JP2003183167 A JP 2003183167A
- Authority
- JP
- Japan
- Prior art keywords
- shark
- iron
- derived
- solution
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000000243 solution Substances 0.000 title claims abstract description 52
- 229920001287 Chondroitin sulfate Polymers 0.000 title claims abstract description 32
- 238000002347 injection Methods 0.000 title claims abstract description 30
- 239000007924 injection Substances 0.000 title claims abstract description 30
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 30
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229940059329 chondroitin sulfate Drugs 0.000 title claims abstract description 24
- 239000000084 colloidal system Substances 0.000 title claims abstract description 24
- 239000007864 aqueous solution Substances 0.000 claims abstract description 37
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000011259 mixed solution Substances 0.000 claims abstract description 6
- 241000251730 Chondrichthyes Species 0.000 claims description 53
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 33
- 229910000358 iron sulfate Inorganic materials 0.000 claims description 30
- 229920002567 Chondroitin Polymers 0.000 claims description 29
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 29
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 12
- 229940102223 injectable solution Drugs 0.000 claims description 10
- -1 chondroitin sulfate alkali metal salt Chemical class 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 abstract 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 description 10
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 6
- 229940032296 ferric chloride Drugs 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003978 infusion fluid Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 4
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960004887 ferric hydroxide Drugs 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 125000000600 disaccharide group Chemical class 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229910002554 Fe(NO3)3·9H2O Inorganic materials 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- UWCDGNNRRPICBV-DBKUKYHUSA-N OS(O)(=O)=O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O Chemical group OS(O)(=O)=O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O UWCDGNNRRPICBV-DBKUKYHUSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940069614 bovine chondroitin sulfate Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- 229910000398 iron phosphate Inorganic materials 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002295694A JP2003183167A (ja) | 2001-10-12 | 2002-10-09 | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001314977 | 2001-10-12 | ||
| JP2001-314977 | 2001-10-12 | ||
| JP2002295694A JP2003183167A (ja) | 2001-10-12 | 2002-10-09 | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009160363A Division JP2009263393A (ja) | 2001-10-12 | 2009-07-07 | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液のプレフィルドシリンジ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003183167A true JP2003183167A (ja) | 2003-07-03 |
| JP2003183167A5 JP2003183167A5 (enrdf_load_stackoverflow) | 2004-12-16 |
Family
ID=27615369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002295694A Pending JP2003183167A (ja) | 2001-10-12 | 2002-10-09 | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003183167A (enrdf_load_stackoverflow) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004346038A (ja) * | 2003-05-23 | 2004-12-09 | Ajinomoto Faruma Kk | 鉄コロイド製剤 |
| JP2007501192A (ja) * | 2003-08-06 | 2007-01-25 | バイオイベリカ ソシエダッド アノニマ | コンドロイチン硫酸の新規な治療的使用 |
| JP2010159294A (ja) * | 2010-03-31 | 2010-07-22 | Ajinomoto Co Inc | 鉄コロイド製剤 |
| JP2013012314A (ja) * | 2011-06-28 | 2013-01-17 | Ngk Spark Plug Co Ltd | スパークプラグおよびスパークプラグの製造方法 |
| JP2013144680A (ja) * | 2013-02-01 | 2013-07-25 | Ajinomoto Co Inc | 鉄コロイド製剤 |
-
2002
- 2002-10-09 JP JP2002295694A patent/JP2003183167A/ja active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004346038A (ja) * | 2003-05-23 | 2004-12-09 | Ajinomoto Faruma Kk | 鉄コロイド製剤 |
| JP2007501192A (ja) * | 2003-08-06 | 2007-01-25 | バイオイベリカ ソシエダッド アノニマ | コンドロイチン硫酸の新規な治療的使用 |
| JP2010159294A (ja) * | 2010-03-31 | 2010-07-22 | Ajinomoto Co Inc | 鉄コロイド製剤 |
| JP2013012314A (ja) * | 2011-06-28 | 2013-01-17 | Ngk Spark Plug Co Ltd | スパークプラグおよびスパークプラグの製造方法 |
| JP2013144680A (ja) * | 2013-02-01 | 2013-07-25 | Ajinomoto Co Inc | 鉄コロイド製剤 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barltrop et al. | The influence of nutritional factors on lead absorption | |
| JP2009263393A (ja) | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液のプレフィルドシリンジ | |
| AU2004253514B2 (en) | Buffered compositions for dialysis | |
| US6689275B1 (en) | Method and pharmaceutical composition for replacing iron losses in dialysis patients | |
| IE910579A1 (en) | Novel protein compositions | |
| AU2199001A (en) | Calcium phosphate nanoclusters and their applications | |
| JP2003183167A (ja) | 鮫由来コンドロイチン硫酸鉄コロイド含有注射液 | |
| CN102526103A (zh) | 一种多种微量元素注射液及其制备方法 | |
| CN110621301B (zh) | 葡萄糖输注溶液组合物 | |
| CN101842385B (zh) | 破骨细胞形成抑制用食品原材料 | |
| AU2018314767B2 (en) | Hemopexin formulations | |
| JP2009221229A (ja) | 鮫由来コンドロイチン硫酸鉄コロイド含有水性製剤 | |
| CS240957B2 (en) | Production method of stabile solution containing iron and selenium | |
| US20050089969A1 (en) | Insulin mimetic amino acid sequences | |
| JPH09221431A (ja) | アルミニウム結合能の低い治療用ヒトアルブミン | |
| KR20250128381A (ko) | 미량 원소 조성물, 이의 제조 방법 및 이의 용도 | |
| JP2004217653A (ja) | 鮫由来コンドロイチン硫酸鉄コロイド含有水性製剤 | |
| JP4573205B2 (ja) | 鉄コロイド製剤 | |
| JP5686830B2 (ja) | 鉄コロイド製剤 | |
| JP5234046B2 (ja) | 鉄コロイド製剤 | |
| CN112543628B (zh) | 含有糖和氨基酸的稳定的输液剂组合物 | |
| RU2629338C1 (ru) | Фармацевтическая композиция для стабилизации гомеостаза и купирования патологических процессов в организме и инъекционная лекарственная форма этой композиции | |
| JPH02108629A (ja) | ラクトフェリンの殺菌方法 | |
| KR20140024862A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| JPS59222405A (ja) | 銀錯体を使用する抗微生物剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071015 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071129 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090707 |